Markets

Marinus Releases Positive Preliminary Data from CDKL5 Study

A generic image of a newspaper with Stock Market as the Headline.
Credit: Shutterstock photo

Marinus Pharmaceuticals, Inc.MRNS , announced positive preliminary data from the initial CDKL5 pediatric patients enrolled in its ongoing phase II study assessing pipeline candidate, ganaxolone, for the treatment of orphan, genetic disorders.

Marinus' share price has declined 77.4% in the past one year, underperforming the Zacks classified Medical-Drugs industry's fall of 13.1% in the same time frame.

Ganaxolone is a CNS-selective GABAA modulator being developed in three different dose forms (IV, capsule, and liquid) intended to maximize therapeutic reach to adult and pediatric patients in both acute and chronic care settings.

The study enrolled four pediatric CDKL5 patients in the cohort, who received up to 1800 mg/kg of ganaxolone per day for an average treatment of five-months. There was a reduction in seizure frequency compared to baseline ranging from 52% to 88% in three of these patients. Two of these patients have completed six-months of treatment and have elected to participate in the study extension. However, one discontinued the study after four-months of treatment due to lack of efficacy.

The study is currently enrolling patients and top-line data is expected in mid-2017. Once this study is complete, Marinus will assess the candidate for a breakthrough therapy and also apply for orphan drug designation from the FDA. We note that the company is focused on developing treatments for patients suffering from epilepsy and neuropsychiatric disorders.

We note that this phase II study is currently accepting patients at five sites in the U.S. and one in Italy. The study is designed to enroll up to 10 patients with each of CDKL5 disorder, Lennox Gastaut Syndrome (LGS) and PCDH19 pediatric epilepsy. The study is actively enrolling CDKL5 and LGS patients Though the PCDH19 cohort of the study has stopped enrolling patients, children are still receiving ganaxolone in the study extension.

Zacks Rank & Key Picks

Marinus currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. ANIK , Sunesis Pharmaceuticals, Inc. SNSS and Enzo Biochem, Inc. ENZ . While Anika and Sunesis sport a Zacks Rank #1 (Strong Buy), Enzo Biochem carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Anika's earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 37.2% in the past one year.

Sunesis' loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.

Enz Biochem's loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 47.9% in the past one year.

Marinus Pharmaceuticals, Inc. Price

Marinus Pharmaceuticals, Inc. Price | Marinus Pharmaceuticals, Inc. Quote

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?

Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report

Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report

Marinus Pharmaceuticals, Inc. (MRNS): Free Stock Analysis Report

Sunesis Pharmaceuticals, Inc. (SNSS): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK SNSS MRNS ENZ

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More